Truist Financial Forecasts Strong Price Appreciation for Integra LifeSciences (NASDAQ:IART) Stock

Integra LifeSciences (NASDAQ:IART) had its target price boosted by stock analysts at Truist Financial from $14.00 to $19.00 in a research note issued on Thursday, Marketbeat reports. The brokerage presently has a “hold” rating on the life sciences company’s stock. Truist Financial’s target price suggests a potential downside of 1.30% from the stock’s current price.

A number of other analysts also recently weighed in on the company. Wall Street Zen upgraded Integra LifeSciences from a “buy” rating to a “strong-buy” rating in a report on Saturday, June 13th. Weiss Ratings raised Integra LifeSciences from a “sell (e+)” rating to a “sell (d-)” rating in a report on Wednesday, May 13th. Wells Fargo & Company upped their price target on Integra LifeSciences from $12.00 to $15.00 and gave the company an “equal weight” rating in a research report on Wednesday, May 6th. BMO Capital Markets initiated coverage on Integra LifeSciences in a research note on Wednesday, July 8th. They issued a “market perform” rating and a $19.00 price target for the company. Finally, Citigroup restated a “neutral” rating and set a $19.00 price objective (up from $16.00) on shares of Integra LifeSciences in a research report on Wednesday, July 8th. One investment analyst has rated the stock with a Buy rating, four have given a Hold rating and two have assigned a Sell rating to the company. According to MarketBeat.com, the company presently has an average rating of “Reduce” and an average price target of $18.33.

Integra LifeSciences Trading Down 3.0%

IART opened at $19.25 on Thursday. Integra LifeSciences has a fifty-two week low of $8.70 and a fifty-two week high of $20.26. The company has a debt-to-equity ratio of 1.75, a current ratio of 3.38 and a quick ratio of 1.95. The firm has a market capitalization of $1.50 billion, a price-to-earnings ratio of -2.98, a PEG ratio of 1.37 and a beta of 1.22. The company’s 50 day moving average price is $16.91 and its two-hundred day moving average price is $13.08.

Integra LifeSciences (NASDAQ:IART) last announced its quarterly earnings results on Tuesday, May 5th. The life sciences company reported $0.54 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.41 by $0.13. The firm had revenue of $391.92 million during the quarter, compared to analysts’ expectations of $381.81 million. Integra LifeSciences had a negative net margin of 30.15% and a positive return on equity of 17.42%. The company’s revenue was up 2.4% on a year-over-year basis. During the same period in the prior year, the company posted $0.41 EPS. Integra LifeSciences has set its FY 2026 guidance at 2.400-2.500 EPS and its Q2 2026 guidance at 0.440-0.520 EPS. As a group, research analysts predict that Integra LifeSciences will post 2.45 earnings per share for the current year.

Hedge Funds Weigh In On Integra LifeSciences

A number of hedge funds have recently bought and sold shares of the company. Rubric Capital Management LP lifted its stake in shares of Integra LifeSciences by 58.4% in the 2nd quarter. Rubric Capital Management LP now owns 7,353,934 shares of the life sciences company’s stock valued at $90,233,000 after purchasing an additional 2,710,262 shares during the period. Paradigm Capital Management Inc. NY grew its stake in Integra LifeSciences by 50.6% during the first quarter. Paradigm Capital Management Inc. NY now owns 4,012,698 shares of the life sciences company’s stock worth $37,800,000 after purchasing an additional 1,347,700 shares during the period. Bank of America Corp DE grew its stake in Integra LifeSciences by 71.4% during the first quarter. Bank of America Corp DE now owns 1,414,509 shares of the life sciences company’s stock worth $13,325,000 after purchasing an additional 589,408 shares during the period. Invenomic Capital Management LP increased its holdings in Integra LifeSciences by 78.3% in the fourth quarter. Invenomic Capital Management LP now owns 1,055,941 shares of the life sciences company’s stock worth $13,115,000 after purchasing an additional 463,729 shares in the last quarter. Finally, Kotler Kevin bought a new stake in Integra LifeSciences in the fourth quarter worth approximately $5,309,000. Institutional investors own 84.78% of the company’s stock.

About Integra LifeSciences

Integra LifeSciences Corporation is a global medical technology company specializing in products and innovations for neurosurgery, regenerative medicine and reconstructive procedures. The company develops and markets surgical instruments, implants and advanced wound care solutions designed to support tissue repair and functional recovery. Its product portfolio includes collagen-based matrices, dural substitutes, hemostatic agents and specialized spinal and peripheral fixation devices.

Founded in 1989 and headquartered in Plainsboro, New Jersey, Integra has expanded its capabilities through targeted acquisitions and internal research efforts.